A Single Center, Randomized, Double-blinded, Placebo-controlled, Open-label, Positive-controlled, Four-way Crossover Study to Assess the Effect of a Single Oral Dose NKTR-118 Administration on QTc Interval Compared to Placebo, Using AVELOX (Moxifloxacin) as a Positive Control, in Healthy Male Subjects.

Trial Profile

A Single Center, Randomized, Double-blinded, Placebo-controlled, Open-label, Positive-controlled, Four-way Crossover Study to Assess the Effect of a Single Oral Dose NKTR-118 Administration on QTc Interval Compared to Placebo, Using AVELOX (Moxifloxacin) as a Positive Control, in Healthy Male Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 20 Nov 2014

At a glance

  • Drugs Naloxegol (Primary)
  • Indications Constipation
  • Focus Adverse reactions
  • Sponsors AstraZeneca
  • Most Recent Events

    • 09 Aug 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 20 Apr 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 28 Mar 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top